-
Ofatumumab Success Story for MS
Our new report from#ECTRIMS2019 on another B cell therapy.
B-cell therapies, which include approved MS therapy Ocrevus (ocrelizumab, by Roche) and rituximab (used off-label) continue to be seen as promising strategies for the treatment of MS.
For Stephen L. Hauser, MD, an investigator in the ASCLEPIOS trials, these results represent a decades-long journey to better understand MS and what he calls a “magnificent success story” in the overall treatment of the disease.
“Ofatumumab shuts down new focal inflammatory activity nearly completely. It reduces relapse-independent disability progression, and at least in the clinical trial data to date, it has a very favorable safety profile. I believe that clinicians should consider the use of highly effective therapy with an agent like ofatumumab very early in the disease course,”
Good news? Sounds like it to me. What do you think?
Sorry, there were no replies found.
Log in to reply.